Nephrology & Urology Clinical Trials

Statistical methods in nephrology & urology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All nephrology & urology trials

321 results

• Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD: Complete Statistical AnalysisIndependent statistical analysis of Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 35NCT01128179
• Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 106NCT03496805
• Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.: Complete Statistical AnalysisIndependent statistical analysis of Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 45NCT00446459
• Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy: Complete Statistical AnalysisIndependent statistical analysis of Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy: primary endpoint results, effect estimate with confidence…Phase NAResults postedn = 28NCT00324675
• Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 4Results postedn = 139NCT00154297
• Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 741NCT01164501
• Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 4Results postedn = 36NCT00965094
• Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 1,179NCT00306787
• Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 833NCT00251004
• Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI): Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 250NCT03366207
• Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03859024).Phase 4Results postedn = 48NCT03859024
• Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®: Complete Statistical AnalysisIndependent statistical analysis of Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 15NCT05900050
• Electrical Muscle Stimulation Versus Resistive Training On Physical Measures, And Fatigue In Hemodialysis Patients: Complete Statistical AnalysisIndependent statistical analysis of Electrical Muscle Stimulation Versus Resistive Training On Physical Measures, And Fatigue In Hemodialysis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 90NCT06079502
• Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney): Complete Statistical AnalysisIndependent statistical analysis of Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03149328).Phase NAResults postedn = 594NCT03149328
• ENVISIONIndependent statistical analysis of A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 240NCT05243550
• ePHex-OLEIndependent statistical analysis of An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 22NCT03938272
• ERECTIndependent statistical analysis of Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 56NCT00737893
• ESTEEMIndependent statistical analysis of Combined Treatment for Mixed Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01959347).Phase 3Results postedn = 480NCT01959347
• Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria: Complete Statistical AnalysisIndependent statistical analysis of Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 16NCT02289755
• Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 240NCT04601272
• Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02165761).Phase NAResults postedn = 42NCT02165761
• Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 769NCT00925600
• Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 70NCT00327340
• Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands: primary endpoint results, effect estimate with confidence interval,…Phase NAResults postedn = 250NCT04626271
• Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 217NCT03317444
• EVIDENCEIndependent statistical analysis of Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment: primary endpoint results, effect estimate with confidence interval,…Phase NAResults postedn = 67NCT02614898
• Exercise Training and Cognitive Function in Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Exercise Training and Cognitive Function in Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03197038).Phase NAResults postedn = 39NCT03197038
• Exploring Life Experience and Lifestyle Intervention Program Among Patients With CKD: Complete Statistical AnalysisIndependent statistical analysis of Exploring Life Experience and Lifestyle Intervention Program Among Patients With CKD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 120NCT01194518
• Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2/3Results postedn = 57NCT00117286
• Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 276NCT04103450
• External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 39NCT00388804
• External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2/3Results postedn = 2NCT01603420
• F-18 Sodium Fluoride in Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of F-18 Sodium Fluoride in Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01240551).Phase 2Results postedn = 60NCT01240551
• FAVORITComplete statistical analysis of FAVORIT, a randomized phase 2/3 trial evaluating high-dose versus low-dose multivitamins in kidney transplant recipients with cardiovascular disease risk.Phase 2/3Results postedn = 4,110NCT00064753
• Feasibility of “At-home” Titration of Solifenacin: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of "At-home" Titration of Solifenacin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00759577).Phase 4Results postedn = 36NCT00759577
• Fecal Microbiota Transplantation (FMT) for MDRO UTI: Complete Statistical AnalysisIndependent statistical analysis of Fecal Microbiota Transplantation (FMT) for MDRO UTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03367910).Phase 1/2Results postedn = 1NCT03367910
• FIDELIO-DKDIndependent statistical analysis of Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 5,734NCT02540993
• FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.Phase 3Results postedn = 7,352NCT02545049
• Fluid Chloride and AKI in Cardiopulmonary Bypass: Complete Statistical AnalysisIndependent statistical analysis of Fluid Chloride and AKI in Cardiopulmonary Bypass: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02668952).Phase 2Results postedn = 30NCT02668952
• Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases: Complete Statistical AnalysisIndependent statistical analysis of Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 18NCT00936975
• Focal Prostate Radio-Frequency Ablation: Complete Statistical AnalysisIndependent statistical analysis of Focal Prostate Radio-Frequency Ablation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02328807).Phase NAResults postedn = 6NCT02328807
• Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT): Complete Statistical AnalysisIndependent statistical analysis of Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00135811).Phase 3Results postedn = 192NCT00135811
• Foot Neuromodulation for Nocturnal Enuresis: Complete Statistical AnalysisIndependent statistical analysis of Foot Neuromodulation for Nocturnal Enuresis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02315560).Phase NAResults postedn = 25NCT02315560
• FRONTIERIndependent statistical analysis of Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 289NCT05085275
• Functional MRI Use in Prostate Radiation Treatment Planning: Complete Statistical AnalysisIndependent statistical analysis of Functional MRI Use in Prostate Radiation Treatment Planning: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01985932).Phase NAResults postedn = 15NCT01985932
• G-MINORIndependent statistical analysis of Genomics in Michigan Impacting Observation or Radiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02783950).Phase NAResults postedn = 356NCT02783950
• Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): Complete Statistical AnalysisIndependent statistical analysis of Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01138124).Phase NAResults postedn = 54,202NCT01138124
• Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03803475).Phase 3Results postedn = 485NCT03803475
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 506NCT00942331
• Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 26NCT02178241

← All therapeutic areas